

# Multi-functional immune-modulating antibody therapeutics for autoimmune disease



<b>IMMUNOLOGY</b>	<b>Non-Clinical</b>
<b>Product Type</b>	Immunoglobulin product (Bispecific antibody)
<b>Indication</b>	Rheumatoid Arthritis → Autoimmune disease (IBD, SLE, etc)
<b>Target</b>	OX40L and TNF
<b>MoA (Mechanism of Action)</b>	<p>Dual modulation of inflammatory cytokine &amp; adaptive immune response → Rebalancing immune system lead long-term immune homeostasis</p> <p>Dual modulation of inflammatory cytokine &amp; adaptive immune responses                      ▶ Rebalancing back to long-term immune homeostasis</p>
<b>Competitiveness</b>	<ul style="list-style-type: none"> <li>• Superior efficacy compared to existing treatments through simultaneous control of inflammatory cytokine and adaptive immunity</li> <li>• Robust response rate without paradoxical effect</li> <li>• Increase remission rate and provide fundamental treatment options through immune system rebalancing and autoantibody reduction</li> <li>• Reduction of systemic side effects through disease site specific action</li> </ul>
<b>Development Stage</b>	Non-Clinical
<b>Route of Administration</b>	Parenteral-Subcutaneous / Intravenous